Browse News
Filter News
Found 220 articles
-
Black Diamond Therapeutics Announces Changes to Board of Directors - April 11, 2024
4/11/2024
Black Diamond Therapeutics, Inc. today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company’s Board of Directors.
-
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
4/7/2024
Black Diamond Therapeutics, Inc. presented real-world evidence of the evolving epidermal growth factor receptor mutation landscape in non-small cell lung cancer, and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies.
-
Black Diamond Therapeutics to Participate in Upcoming April 2024 Investor Conferences
4/3/2024
Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced its participation in upcoming investor conferences.
-
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/21/2024
Disc Medicine, Inc. (NASDAQ:IRON) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent program and corporate developments.
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/12/2024
Black Diamond Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
3/5/2024
Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, announced an upcoming oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.
-
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2/28/2024
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET in Boston, MA.
-
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
1/4/2024
Black Diamond Therapeutics, Inc. provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.
-
Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM
12/13/2023
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535.
-
Oculis Reports Q3 2023 Financial Results and Provides Company Update
11/15/2023
Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced third quarter financial results for the period ended September 30, 2023, and an overview of the Company’s progress.
-
Black Diamond Therapeutics to Participate in Upcoming November 2023 Investor Conferences
11/7/2023
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats during two upcoming investor conferences.
-
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
11/7/2023
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the third quarter ended September 30, 2023 and highlighted additional corporate updates and milestones.
-
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade GliomaStudy tests targeted agent, BDTX-1535, an EGFR inhibitor with brain-penetrant properties
11/6/2023
The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of BDTX-1535, an experimental drug targeting oncogenic EGFR (epidermal growth factor receptor) mutations in patients with recurrent high-grade glioma.
-
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/6/2023
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Rodent Optic Nerve Head Wins the 49th Annual Nikon Small World Photo Microscopy Competition
10/17/2023
Nikon Instruments Inc. unveiled the winners of the 49th annual Nikon Small World Photomicrography Competition.
-
Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535
10/14/2023
Black Diamond Therapeutics, Inc. presented results demonstrating encouraging response durability of BDTX-1535 in patients with locally advanced or metastatic non-small cell lung cancer.
-
Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/4/2023
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced forthcoming presentations during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 11-15, 2023.
-
Black Diamond Therapeutics Announces CEO Transition
9/18/2023
Black Diamond Therapeutics, Inc. announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately.
-
Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer
9/11/2023
Black Diamond Therapeutics, Inc. today announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer in the ongoing Phase 1 clinical study evaluating BDTX-1535.
-
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
9/11/2023
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.